Recent Updates
Recently added Catalysts
SVRA Negative Sentiment

Savara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRA

Key Takeaway: Savara Inc. is being sued for alleged violations of securities laws by shareholders who purchased shares between March 4, 2024, and May 23, 2025. The complaint claims that the company provided misleading statements about the submission of its biologics license application (BLA) for MOLBREEVI, a treatment for pulmonary alveolar proteinosis. Investors are concerned that the FDA is unlikely to approve the BLA in its current form, which could lead to capital raising needs for the company. Shareholders have until November 7, 2025, to register for participation in the class action.
Price reaction · baseline $4.23 (2025-10-21 close) · hit after-hours · 2 other SVRA headline(s) in the window, move may be shared
day 0 close · peak
-2.8%

Market Sentiment Analysis

CONCERNS & RISKS

  • Savara Inc. is facing a lawsuit alleging securities law violations.
  • The lawsuit includes claims of misleading public statements regarding the BLA for MOLBREEVI.
  • There are concerns about the potential delay in regulatory approval for MOLBREEVI, impacting financial stability.
  • Savara may be required to raise additional capital due to these delays.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.4%
average across 3 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
MST-188
Phase 3 · Vaso-occlusive Crisis

Full Press Release Details

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA).
Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 4, 2024 to May 23, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.
DEADLINE: November 7, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=173219&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SVRA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 7, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor

Frequently Asked Questions

What is the class period for Savara Inc. shareholders?

The class period for Savara Inc. shareholders is from March 4, 2024, to May 23, 2025.

What allegations are made against Savara Inc.?

The allegations claim Savara made false statements about the approval of MOLBREEVI BLA.

What is the deadline to register for the class action?

The deadline to register for the class action is November 7, 2025.

Is there a fee to participate in this class action?

There is no cost or obligation to participate in this class action.

How to contact the Gross Law Firm for more information?

You can contact the Gross Law Firm at dg@securitiesclasslaw.com or call 646-453-8903.

Last updated: Oct 22, 2025